Behind the Breakthrough: The QC Systems That Make Recombinant Collagen Superior

Overview

Recombinant collagen has become an ideal alternative to traditional animal-derived collagen due to its advantages of zero viral risk, low immunogenicity, good water solubility, and high batch-to-batch consistency. It is widely used in biopharmaceuticals, tissue engineering, and premium skincare. Establishing a rigorous, full-process quality control system is the cornerstone for ensuring the safety, efficacy, and consistency of recombinant collagen products.

Types of Recombinant Collagen

As a high-tech company supplying key raw materials for the biopharmaceutical field, Hzymes was invited to showcase its technologies at the exhibition.

Collagen is the most abundant protein in the human body, accounting for 25%–30% of total protein. It is widely distributed in the skin, bones, tendons, and blood vessels, maintaining structural integrity, elasticity, and tensile strength. Based on structural characteristics, collagen is classified into fibrillar collagen (types I, II, III, V, XI, XXI, XXVII) and non-fibrillar collagen (types IV, VI, VII, VIII, IX, X, XII–XXVIII). In medical aesthetics and cosmetics, type I and type III collagen are the most widely used.

Traditional collagen is extracted from animal tissues (such as bovine Achilles tendon, porcine skin, and fish scales) and presents challenges including poor water solubility, risk of viral contamination, high immunogenicity, and significant batch variability. Recombinant collagen, produced through recombinant DNA technology, modifies human collagen gene sequences and expresses them in host cells followed by purification—resulting in recombinant human collagen, humanized collagen, or collagen-like polypeptides. With excellent biocompatibility, high biological activity, and low immunogenicity, recombinant collagen has become a “star molecule” in medical devices and the medical aesthetics industry.

Production Process of Recombinant Collagen

As a high-tech provider of core raw materials for the biopharmaceutical industry, Hzymes was invited to present at the exhibition.

Recombinant collagen can be expressed in E. coli, yeast, plants, baculovirus systems, or mammalian cells, with E. coli and yeast being the most common. E. coli and yeast lack the post-translational modification machinery found in animal cells, thus requiring the addition of corresponding recombinant enzymes. Plant, baculovirus, and mammalian systems produce lower yields but provide complete triple-helix structure and improved thermal stability.

The production workflow includes:

Gene construction:

Selecting target gene segments and collagen domains, designing collagen (Gly-X-Y)n sequences, and constructing the expression vector. Sometimes, specific host genes must be knocked out to optimize collagen expression and increase yield.

Engineering cell line construction:

Engineered cells are the starting point and core of production, ensuring high expression, correct folding, and biological activity.

– E. coli offers clear genetics, rapid growth, and high expression but lacks glycosylation and tends to form inclusion bodies.
– Yeast supports high-density, large-scale fermentation at lower cost but may contain high polysaccharide levels in the culture supernatant.
– Mammalian cells provide native-like post-translational modifications and activity but are expensive and demanding to culture.

Cell culture:

Conditions are set based on cell characteristics—temperature, pH, dissolved oxygen, CO₂ level—and carried out at high density. This includes cell bank establishment and control, process control (culture and extraction), medium optimization, and scale-up studies.

Downstream purification:

Steps include cell disruption and clarification, precipitation and crude purification, chromatography (the core step), viral and endotoxin removal, and concentration/buffer exchange. After lysis releases the protein, initial purification (e.g., salting-out, organic solvent precipitation, ultrafiltration) is performed before fine purification via gel filtration, hydrophobic chromatography, or affinity chromatography.

Quality characterization:

Structural verification covers primary structure, higher-order structure (e.g., triple helix), and post-translational modifications. Quality control includes physicochemical testing, purity and impurity analysis, bioactivity assays, stability testing, sterility testing, and immunogenicity assessment.

Formulation development:

Includes developability assessment, formulation process optimization, and GMP production. Dosage form and packaging (prefilled syringes, vials, etc.) are determined based on product characteristics, followed by sterile filling, inspection, and storage.

Critical Quality Attributes of Recombinant Collagen

As a high-tech provider of core raw materials in the biopharmaceutical field, Hzymes was invited to attend the exhibition.

In 2021, the National Medical Products Administration (NMPA) issued the Guiding Principles for the Nomenclature of Recombinant Collagen Biomaterials and the Classification Principles for Recombinant Collagen Medical Products, setting clear regulatory standards.

The 2023 implementation of YY/T 1849-2022 “Recombinant Collagen” marked the world’s first comprehensive industry standard defining quality specifications, analytical methods, and technical indicators. The subsequent YY/T 1888-2023 “Recombinant Humanized Collagen” provides further standardization for quality control, testing metrics, and analytical methodology.

Physicochemical properties

Identification

Impurities

Hzymes – Recombinant Protein Quality Control Solutions & CDMO Services

As a high-tech company providing core raw materials for the biopharmaceutical industry, Hzymes was invited to present at the exhibition.

The core competitiveness of recombinant collagen lies in strict process control and a comprehensive, multi-dimensional, traceable quality research system. Leveraging its biopharmaceutical QC platform, Hzymes offers complete quality testing solutions—from raw material inspection and impurity control to final product release.

Hzymes has developed a protein directed evolution platform and the Hevo AI+ design platform, with extensive experience in recombinant protein design, development, and large-scale manufacturing. The company provides GMP-grade production services, supported by flexible fermentation capacities ranging from 5 L, 50 L, 500 L, 5 T, 10 T, 30 T, 60 T to 100 T, along with multiple chromatography systems and freeze-drying platforms (0.2 m², 0.5 m², 2 m², 10 m², 20 m²).